The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RCUS | +0% | -16.58% | -3.56% | -1% |
| S&P | +14.5% | +93.32% | +14.09% | +144% |
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Arcus was one of the few winners in the turbulent biotech space last month.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $160.00M | 310.3% |
| Gross Profit | $158.00M | 327.0% |
| Gross Margin | 98.75% | 3.9% |
| Market Cap | $861.90M | -37.8% |
| Market Cap / Employee | $1.37M | 0.0% |
| Employees | 627 | 8.7% |
| Net Income | $0.00M | 100.0% |
| EBITDA | -$6.00M | 94.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $248.00M | 59.0% |
| Accounts Receivable | $15.00M | -46.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $97.00M | 0.0% |
| Short Term Debt | $12.00M | 9.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -26.36% | -5.7% |
| Return On Invested Capital | -30.23% | 1.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$133.00M | -41.5% |
| Operating Free Cash Flow | -$133.00M | -41.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.20 | 2.41 | 1.49 | 1.62 | -17.09% |
| Price to Sales | 5.31 | 5.29 | 5.48 | 3.31 | -41.10% |
| Price to Tangible Book Value | 2.20 | 2.41 | 1.49 | 1.62 | -17.09% |
| Enterprise Value to EBITDA | -3.56 | -5.46 | 1.38 | -10.82 | 161.99% |
| Return on Equity | -49.8% | -59.8% | -63.2% | -50.3% | 21.40% |
| Total Debt | $58.00M | $159.00M | $60.00M | $109.00M | 890.91% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
